ARTICLE
22 January 2021

COVID-19 Key EU Developments, Policy & Regulatory Update No. 30

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
This regular alert covers key regulatory EU developments related to the COVID-19 situation. It does not purport to provide an exhaustive overview of developments and contains no analysis or opinion.
European Union Coronavirus (COVID-19)
Kaarli H. Eichhorn’s articles from Jones Day are most popular:
  • with Inhouse Counsel

This regular alert covers key regulatory EU developments related to the COVID-19 situation. It does not purport to provide an exhaustive overview of developments and contains no analysis or opinion.

LATEST KEY DEVELOPMENTS

Competition & State Aid

  • European Commission addresses State aid support in Communication on tackling nonperforming loans in the aftermath of COVID-19 pandemic
  • European Commission Executive Vice-President Margrethe Vestager speech on hydrogenrelated projects, including potential support by COVID-19 recovery funds
  • EU approves new and amended Member State measures to support the economy

Trade / Export Controls

  • European Parliament and EU Member States reach political agreement on new Customs Programme for 2021-2027
  • European Commission publishes second Counterfeit and Piracy Watch List

Medicines, Medical Devices, and Personal Protective Equipment

  • European Commission grants conditional marketing authorization for Pfizer/BioNTech COVID-19 vaccine
  • Moderna COVID-19 vaccine: European Commission purchases additional doses and EMA accelerates approval timeline
  • European Commission adopts a proposal for a Council Recommendation on use and validation of rapid COVID-19 tests

Cybersecurity, Privacy & Data Protection

  • European Medicines Agency pursues investigation of cyberattack

To view the full article, please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More